Stockscreener 앱 받기
5.88
4.26%
0.24
시간 외 거래:
6.09
0.21
+3.57%
전일 마감가:
$5.64
열려 있는:
$5.77
하루 거래량:
234.83K
Relative Volume:
0.22
시가총액:
$159.21M
수익:
-
순이익/손실:
$-49.81M
주가수익비율:
-2.7273
EPS:
-2.156
순현금흐름:
$-42.93M
1주 성능:
-10.09%
1개월 성능:
+51.16%
6개월 성능:
+176.06%
1년 성능:
-56.57%
1일 변동 폭
$5.6101
$5.96
1주일 범위
$5.52
$6.5909
52주 변동 폭
$1.60
$15.04
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
ANRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
5.88 | 152.71M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Relative strength of Alto Neuroscience Inc. in sector analysisJuly 2025 Market Mood & Advanced Technical Analysis Signals - newser.com
Will Alto Neuroscience Inc. stock recover faster than market2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - newser.com
What indicators show strength in Alto Neuroscience Inc.July 2025 Breakouts & Capital Protection Trading Alerts - newser.com
How risky is Alto Neuroscience Inc. stock now2025 Market Sentiment & Consistent Growth Equity Picks - newser.com
What earnings revisions data tells us about Alto Neuroscience Inc.Treasury Yields & Weekly Hot Stock Watchlists - newser.com
How to manage a losing position in Alto Neuroscience Inc.Forecast Cut & Smart Money Movement Alerts - newser.com
How to track smart money flows in Alto Neuroscience Inc.2025 Big Picture & Verified Entry Point Signals - newser.com
What MACD signals say about Alto Neuroscience Inc.Portfolio Gains Report & Stock Timing and Entry Methods - newser.com
Can Alto Neuroscience Inc. stock sustain free cash flow growthQuarterly Profit Review & Real-Time Buy Signal Notifications - newser.com
When is the best time to exit Alto Neuroscience Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
What the charts say about Alto Neuroscience Inc. today2025 Year in Review & Smart Money Movement Tracker - newser.com
What Fibonacci levels say about Alto Neuroscience Inc. reboundWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - newser.com
Will Alto Neuroscience Inc. stock benefit from commodity supercycleQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Why Alto Neuroscience Inc. stock is a must watch in 2025Gold Moves & Fast Exit Strategy with Risk Control - newser.com
How to forecast Alto Neuroscience Inc. trends using time series2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
Alto Neuroscience (NYSE:ANRO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Alto Neuroscience Board Sued Over Study Result, 70% Stock Drop - Bloomberg Law News
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewswire
Alto Neuroscience Execs Sued Over Rosy Drug Claims - Law360
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What drives Alto Neuroscience Inc stock priceSmall Cap Stock Opportunities & Outperform With Our Smart Trading Calculator - earlytimes.in
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Alto Neuroscience Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
Optimistic Buy Rating for Alto Neuroscience, Inc. Amidst Promising Developments and FDA Fast Track Designation - TipRanks
Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate - Yahoo Finance
Why retail traders accumulate Alto Neuroscience Inc. stock2025 Top Decliners & Intraday High Probability Alerts - newser.com
Alto Neuroscience: Evaluating Valuation After FDA Fast Track Win for ALTO-101 - simplywall.st
Alto Neuroscience Stock Soars Amid FDA Fast-Track Approval - StocksToTrade
Alto Neuroscience Stock Soars as FDA Grants Fast-Track for Schizophrenia Treatment - timothysykes.com
What moving averages say about Alto Neuroscience Inc.2025 Geopolitical Influence & Risk Controlled Daily Trade Plans - newser.com
Smart tools for monitoring Alto Neuroscience Inc.’s price actionJuly 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Can Alto Neuroscience Inc. stock rebound after recent weaknessSell Signal & Smart Allocation Stock Tips - newser.com
Alto Neuroscience Soars After FDA Fast Track Decision - timothysykes.com
Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation - 富途牛牛
Rare Earth, Biotech, And Hotpot Stocks Steal The Show - Finimize
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug - Stocktwits
Will Alto’s Innovative Research Drive its Market Surplus? - StocksToTrade
Alto Neuroscience stock soars after FDA grants Fast Track designation - Investing.com
Alto Neuroscience’s Schizophrenia Treatment Granted FDA Fast Track Designation - Contract Pharma
FDA grants fast track designation to Alto’s schizophrenia drug By Investing.com - Investing.com Australia
Alto Neuroscience receives FDA fast track designation for Alto-101 - MarketScreener
FDA grants fast track designation to Alto’s schizophrenia drug - Investing.com India
Alto Neuroscience granted fast track designation for ALTO-101 - TipRanks
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia | Fat Pitch Financials - FinancialContent
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - The Joplin Globe
FY2025 Earnings Forecast for ANRO Issued By Chardan Capital - MarketBeat
Will Alto Neuroscience Inc. stock rally after Fed decisionsMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Should you hold or exit Alto Neuroscience Inc. nowChart Signals & High Win Rate Trade Alerts - newser.com
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
자본화:
|
볼륨(24시간):